Chemotherapeutics for Acute Erythroid Leukemia: Research, Present and Future

Author(s): Zexi Liao, Jiaxin Li, Jingjing Wu, Jing Liu*, Shuming Sun*

Journal Name: Current Molecular Medicine

Volume 21 , Issue 10 , 2021

Become EABM
Become Reviewer
Call for Editor


Acute erythroid leukemia (AEL) is a subtype of acute myeloid leukemia (AML) with features such as accumulation of maturation-arrested erythroblasts. Compared with AML, the progression of AEL is faster and the prognosis to available therapy is worse. However, its categorization is still being updated and the pathophysiology of AEL is still under research, making diagnosis and chemotherapy challenging for physicians. To achieve better outcomes, therapies should be optimized and new drugs should be developed. In this review, we summarize current strategies of diagnosis and therapies of AEL, and discuss prospective targets for chemotherapeutic agents based on the biological characteristics of AEL neoplastic cells as well as transcriptional factors and pathways related to erythroid differentiation.

Keywords: Acute erythroid leukemia, acute myeloid leukemia, chemotherapeutic agents, erythroid differentiation, GATA-1, GATA-2, Gfi1b, EKLF, EPO-related pathways.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 21 January, 2021
Page: [819 - 831]
Pages: 13
DOI: 10.2174/1566524021666210121142316
Price: $65

Article Metrics

PDF: 512